Zimmer Biomet Company Top Insiders
ZBH Stock | USD 132.61 4.74 3.71% |
Under 80 percent of all Zimmer Biomet's insiders are aggressively buying. The analysis of insiders' sentiment of trading Zimmer Biomet Holdings stock suggests that a large number of insiders are very bullish at this time. Zimmer Biomet employs about 18 K people. The company is managed by 47 executives with a total tenure of roughly 321 years, averaging almost 6.0 years of service per executive, having 382.98 employees per reported executive.
David Dvorak CEO CEO and President and Director |
Larry Glasscock Chairman Independent Non-Executive Chairman of the Board |
Zimmer Biomet's Insider Buying Vs Selling
80
Selling | Buying |
Latest Trades
2024-02-22 | Chad F Phipps | Disposed 26156 @ 128.62 | View | ||
2023-08-30 | Sreelakshmi Kolli | Acquired 1000 @ 120.37 | View | ||
2023-08-28 | Robert Hagemann | Acquired 2000 @ 116.48 | View | ||
2023-08-25 | Michael W Michelson | Acquired 1300 @ 115.5 | View | ||
2023-08-23 | Arthur J Higgins | Acquired 1000 @ 115.61 | View |
Monitoring Zimmer Biomet's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Zimmer |
Zimmer Biomet's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Zimmer Biomet's future performance. Based on our forecasts, it is anticipated that Zimmer will maintain a workforce of under 18000 employees by April 2024.Zimmer Biomet's latest congressional trading
Congressional trading in companies like Zimmer Biomet Holdings, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Zimmer Biomet by those in governmental positions are based on the same information available to the general public.
2022-11-28 | Representative Van Taylor | Disposed $100K to $250K | Verify | ||
2022-07-28 | Representative Lois Frankel | Disposed Under $15K | Verify | ||
2021-09-30 | Representative Susie Lee | Disposed $15K to $50K | Verify | ||
2021-08-06 | Representative Charles J. "Chuck" Fleischmann | Disposed Under $15K | Verify | ||
2016-12-16 | Senator Jack Reed | Acquired Under $15K | Verify |
Zimmer Biomet Management Team Effectiveness
The company has Return on Asset of 0.044 % which means that on every $100 spent on assets, it made $0.044 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0836 %, implying that it generated $0.0836 on every 100 dollars invested. Zimmer Biomet's management efficiency ratios could be used to measure how well Zimmer Biomet manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Capital Employed is estimated to decrease to 0.07. The current Return On Assets is estimated to decrease to 0.05. As of now, Zimmer Biomet's Asset Turnover is decreasing as compared to previous years.The current Common Stock Shares Outstanding is estimated to decrease to about 164.9 M. The current Net Income Applicable To Common Shares is estimated to decrease to about 252.8 M
Zimmer Biomet Workforce Comparison
Zimmer Biomet Holdings is rated third in number of employees category among related companies. The total workforce of Health Care industry is at this time estimated at about 153,593. Zimmer Biomet retains roughly 18,000 in number of employees claiming about 12% of equities under Health Care industry.
Zimmer Biomet Profit Margins
The company has Net Profit Margin of 0.14 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.24 %, which entails that for every 100 dollars of revenue, it generated $0.24 of operating income.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.8 | 0.6306 |
|
| |||||
Operating Profit Margin | 0.22 | 0.1876 |
|
|
Zimmer Biomet Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Zimmer Biomet insiders, such as employees or executives, is commonly permitted as long as it does not rely on Zimmer Biomet's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Zimmer Biomet insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-03-01 | 0.75 | 30 | 40 | 193,004 | 134,290 |
2023-12-01 | 1.0 | 10 | 10 | 4,346 | 54,956 |
2023-09-01 | 6.6667 | 20 | 3 | 31,806 | 8,078 |
2023-06-01 | 15.0 | 30 | 2 | 15,737 | 825.00 |
2023-03-01 | 1.625 | 26 | 16 | 162,668 | 83,458 |
2022-12-01 | 1.8571 | 13 | 7 | 17,129 | 26,399 |
2022-09-01 | 2.5 | 10 | 4 | 6,105 | 8,181 |
2022-06-01 | 15.5 | 31 | 2 | 22,869 | 698.00 |
2022-03-01 | 9.75 | 39 | 4 | 467,147 | 64,913 |
2021-12-01 | 0.4839 | 15 | 31 | 64,115 | 200,119 |
2021-09-01 | 6.0 | 12 | 2 | 55,755 | 4,767 |
2021-06-01 | 10.0 | 30 | 3 | 18,583 | 1,677 |
2021-03-01 | 1.5789 | 30 | 19 | 288,100 | 46,869 |
2020-12-01 | 1.1538 | 15 | 13 | 44,019 | 79,541 |
2020-09-01 | 3.6667 | 11 | 3 | 7,069 | 6,288 |
2020-06-01 | 15.5 | 31 | 2 | 25,622 | 9,717 |
2020-03-01 | 2.3571 | 33 | 14 | 391,443 | 47,148 |
2019-12-01 | 1.1111 | 20 | 18 | 32,522 | 48,096 |
2019-09-01 | 1.8571 | 13 | 7 | 114,086 | 74,745 |
2019-06-01 | 7.5 | 30 | 4 | 25,796 | 11,639 |
2019-03-01 | 3.5385 | 46 | 13 | 365,528 | 22,627 |
2018-12-01 | 8.0 | 16 | 2 | 65,078 | 12,622 |
2018-09-01 | 2.1429 | 15 | 7 | 61,162 | 71,701 |
2018-06-01 | 3.7143 | 26 | 7 | 31,431 | 20,582 |
2018-03-01 | 5.8333 | 35 | 6 | 588,586 | 48,557 |
2017-12-01 | 1.8571 | 13 | 7 | 339,212 | 25,762 |
2017-09-01 | 1.5556 | 14 | 9 | 26,361 | 33,282 |
2017-06-01 | 1.7619 | 37 | 21 | 174,048 | 283,208 |
2017-03-01 | 1.6818 | 37 | 22 | 523,484 | 270,163 |
2016-12-01 | 5.0 | 10 | 2 | 6,975 | 10,100 |
2016-09-01 | 0.9167 | 11 | 12 | 19,968 | 66,618 |
2016-06-01 | 3.0909 | 34 | 11 | 23,585 | 50,622 |
2016-03-01 | 1.5714 | 33 | 21 | 574,565 | 40,720,036 |
2015-12-01 | 2.25 | 9 | 4 | 6,733 | 10,844 |
2015-06-01 | 1.0385 | 54 | 52 | 798,845 | 209,284 |
2015-03-01 | 1.1429 | 24 | 21 | 170,302 | 139,375 |
2014-12-01 | 0.875 | 14 | 16 | 91,430 | 138,016 |
2014-09-01 | 1.6667 | 10 | 6 | 82,642 | 92,473 |
Zimmer Biomet Notable Stakeholders
A Zimmer Biomet stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Zimmer Biomet often face trade-offs trying to please all of them. Zimmer Biomet's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Zimmer Biomet's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
David Dvorak | CEO and President and Director | Profile | |
Larry Glasscock | Independent Non-Executive Chairman of the Board | Profile | |
Bryan Hanson | Chairman of the Board, President, Chief Executive Officer | Profile | |
Coleman Lannum | Senior Vice President - Investor Relations | Profile | |
Matt Abernethy | CPA, Vice President Investor Relations | Profile | |
Ellison Humphrey | Senior Vice President, Chief Transformation Officer | Profile | |
Daniel Florin | CFO, Senior Vice President | Profile | |
Robert Marshall | Vice President - Investor Relations, Treasurer | Profile | |
David Nolan | Group President of Biologics, Extremities, Sports Medicine, Surgical, Trauma, Foot and Ankle and Bone Healing | Profile | |
Joseph Cucolo | President Americas | Profile | |
Derek Davis | Chief Accounting Officer, Vice President, Controller | Profile | |
Ivan Tornos | Group President - Global Businesses and Americas | Profile | |
Aure Bruneau | Group President Spine, CMF, Thoracic and Surgery Assisting Technology | Profile | |
Katarzyna MazurHofsaess | President Europe, Middle East and Africa | Profile | |
Suketu Upadhyay | Chief Financial Officer, Executive Vice President | Profile | |
Sang Yi | President Asia Pacific | Profile | |
Adam Johnson | Group President Spine, Dental, CMF and Thoracic | Profile | |
Daniel Williamson | Group President Joint Reconstruction | Profile | |
Chad Phipps | Senior Vice President, General Counsel, Secretary | Profile | |
Tony Collins | Chief Accounting Officer, Vice President Controller | Profile | |
Stuart Kleopfer | President Americas | Profile | |
Robert Delps | President Americas | Profile | |
Arthur Higgins | Independent Director | Profile | |
Michael Michelson | Independent Director | Profile | |
Cecil Pickett | Independent Director | Profile | |
Jeffrey Rhodes | Director | Profile | |
Paul Bisaro | Independent Director | Profile | |
Christopher Begley | Lead Independent Director | Profile | |
Betsy Bernard | Independent Director | Profile | |
Maria Hilado | Independent Director | Profile | |
Syed Jafry | Independent Director | Profile | |
Michael Farrell | Independent Director | Profile | |
Zachary CPA | Director Relations | Profile | |
Gail Boudreaux | Independent Director | Profile | |
Robert Hagemann | Independent Director | Profile | |
Angela Main | Global VP | Profile | |
Sreelakshmi Kolli | Independent Director | Profile | |
Didier Deltort | President - Europe, Middle East and Africa | Profile | |
Carrie Nichol | Chief Accounting Officer, Vice President Controller | Profile | |
Nitin Goyal | Chief Science, Technology and Innovation Officer | Profile | |
Wilfred Zuilen | President - Europe, Middle East and Africa | Profile | |
Zeeshan Tariq | Senior Officer | Profile | |
Keri Mattox | Senior Vice President - Investor Relations, Chief Communications Officer | Profile | |
Rachel Ellingson | Senior Vice President Chief Strategy Officer, Executive Officer | Profile | |
Nitin MD | Technology Science | Profile | |
Paul Stellato | Controller VP | Profile | |
Lori Winkler | Chief Human Resource Officer, Senior Vice President | Profile |
About Zimmer Biomet Management Performance
The success or failure of an entity such as Zimmer Biomet Holdings often depends on how effective the management is. Zimmer Biomet management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Zimmer management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Zimmer management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for 2024 | ||
Return On Capital Employed | 0.07 | 0.07 | |
Return On Assets | 0.05 | 0.05 | |
Return On Equity | 0.08 | 0.08 |
The data published in Zimmer Biomet's official financial statements usually reflect Zimmer Biomet's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Zimmer Biomet Holdings. For example, before you start analyzing numbers published by Zimmer accountants, it's critical to develop an understanding of what Zimmer Biomet's liquidity, profitability, and earnings quality are in the context of the Health Care Equipment & Supplies space in which it operates.
Please note, the presentation of Zimmer Biomet's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Zimmer Biomet's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Zimmer Biomet's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Zimmer Biomet Holdings. Please utilize our Beneish M Score to check the likelihood of Zimmer Biomet's management manipulating its earnings.
Zimmer Biomet Workforce Analysis
Traditionally, organizations such as Zimmer Biomet use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Zimmer Biomet within its industry.Zimmer Biomet Manpower Efficiency
Return on Zimmer Biomet Manpower
Revenue Per Employee | 410.8K | |
Revenue Per Executive | 157.3M | |
Net Income Per Employee | 56.9K | |
Net Income Per Executive | 21.8M | |
Working Capital Per Employee | 97.3K | |
Working Capital Per Executive | 37.3M |
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zimmer Biomet Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Zimmer Biomet Holdings information on this page should be used as a complementary analysis to other Zimmer Biomet's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Complementary Tools for Zimmer Stock analysis
When running Zimmer Biomet's price analysis, check to measure Zimmer Biomet's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zimmer Biomet is operating at the current time. Most of Zimmer Biomet's value examination focuses on studying past and present price action to predict the probability of Zimmer Biomet's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zimmer Biomet's price. Additionally, you may evaluate how the addition of Zimmer Biomet to your portfolios can decrease your overall portfolio volatility.
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |
Is Zimmer Biomet's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zimmer Biomet. If investors know Zimmer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zimmer Biomet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.16) | Dividend Share 0.96 | Earnings Share 4.88 | Revenue Per Share 35.43 | Quarterly Revenue Growth 0.063 |
The market value of Zimmer Biomet Holdings is measured differently than its book value, which is the value of Zimmer that is recorded on the company's balance sheet. Investors also form their own opinion of Zimmer Biomet's value that differs from its market value or its book value, called intrinsic value, which is Zimmer Biomet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zimmer Biomet's market value can be influenced by many factors that don't directly affect Zimmer Biomet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zimmer Biomet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zimmer Biomet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zimmer Biomet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.